Coloplast A/S (CLPBY) Stock Price, News & Analysis

Company Overview

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste. The continence care segment offers catheters, drainage bags and related supplies for individuals with bladder control issues. The company’s wound and skin care portfolio includes advanced dressings, negative-pressure wound therapy and pressure ulcer prevention products, while its interventional urology line features devices for minimally invasive procedures and diagnostics in urological conditions.

Founded in 1957 by Danish entrepreneur Aage Louis-Hansen, Coloplast began when Louis-Hansen developed the first adhesive ostomy bag to help his wife manage her postoperative care. Since then, the company has grown from a small family operation into a publicly listed corporation on the Copenhagen Stock Exchange, with an American depositary receipt program trading under the symbol CLPBY in the U.S. The company is led by President and CEO Peter Clemmensen, who has overseen continued expansion of R&D and manufacturing capabilities.

Headquartered in Humlebæk, Denmark, Coloplast operates manufacturing and research facilities across Europe and North America, supported by a global sales and distribution network. Its products are available in more than 100 countries, with regional offices and partnerships that ensure local market support and training for healthcare professionals. The company places a strong emphasis on customer proximity and collaborative development to address the evolving needs of patients and clinicians worldwide.

Key Stats

• Today's Range: $5.97 to $6.07
• 50-Day Range: $5.70 to $6.62
• 52-Week Range: $5.64 to $10.03
• Volume: 265,929 shs
• Average Volume: 504,141 shs
• Market Capitalization: $13.61 billion
• P/E Ratio: 43.14
• Dividend Yield: 1.32%
• Price Target: N/A
• Consensus Rating: Hold

Coloplast A/S Stock Analysis - MarketRank™

Coloplast A/S scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Hold

Consensus Rating

Coloplast A/S has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Coloplast A/S has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.50%

Earnings Growth

Earnings for Coloplast A/S are expected to grow by 7.50% in the coming year, from $0.40 to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Coloplast A/S is 43.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 46.34.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coloplast A/S is 43.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.81.

Price to Earnings Growth Ratio

Coloplast A/S has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Coloplast A/S has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Coloplast A/S has been sold short.

Short Interest Ratio / Days to Cover

Coloplast A/S has a short interest ratio ("days to cover") of 0.16, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coloplast A/S has recently decreased by 36.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Coloplast A/S pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Coloplast A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Coloplast A/S is 57.14%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Coloplast A/S will have a dividend payout ratio of 18.60% next year. This indicates that Coloplast A/S will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Coloplast A/S to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coloplast A/S insiders have not sold or bought any company stock.

Percentage Held by Institutions

Coloplast A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/04/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CLPBY
• Previous Symbol: NASDAQ:CLPBY
• CIK: 1294325
• Web: www.coloplast.com
• Phone: (454) 911-1111
• Fax: N/A
• Employees: 17,156
• Year Founded: 1957

Profitability

• EPS (Trailing Twelve Months): $0.14
• Trailing P/E Ratio: 43.14
• Forward P/E Ratio: 15.10
• P/E Growth: 1.91
• Net Income: $538.49 million
• Net Margins: 7.46%
• Pretax Margin: 12.24%
• Return on Equity: 33.15%
• Return on Assets: 10.22%

Debt

• Debt-to-Equity Ratio: 1.66
• Current Ratio: 1.75
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: $4.13 billion
• Price / Sales: 3.30
• Cash Flow: $0.36 per share
• Price / Cash Flow: 16.84
• Book Value: $1.06 per share
• Price / Book: 5.70

Miscellaneous

• Outstanding Shares: 2,253,670,000
• Free Float: N/A
• Market Cap: $13.61 billion
• Optionable: Not Optionable
• Beta: 0.22